A Phase II, Multicentre, Open Label Clinical Trial to Assess the Efficacy and Toxicity of Induction and Consolidation With CPX-351 for Patients Aged 60 to 75 Years With Secondary or High-risk Acute Myeloid Leukemia
Latest Information Update: 25 Sep 2023
At a glance
- Drugs Cytarabine/daunorubicin (Primary) ; Granulocyte colony-stimulating factors
- Indications Acute myeloid leukaemia
- Focus Therapeutic Use
- Acronyms LAMVYX
- 07 Sep 2022 Status changed from active, no longer recruiting to completed.
- 09 Jul 2021 Status changed from recruiting to active, no longer recruiting.
- 05 Jul 2021 Planned End Date changed from 1 Dec 2022 to 1 Jan 2022.